Providing answers for cancer patients

curasight

Curasight A/S Half-year report Q2 2024

THI

In this document, the following definitions shall apply unless otherwise specified: "the Company" or "Curasight" refers to Curasight A/S, CVR no. 35249389.

CEO letter

Highlights

About Curasight

The Company 2200 København N Registered office: København N CVR no.: 35 24 93 89 Financial year: 01.01 - 31.12

Key figures and selected posts

Q2 (2024-04-01 - 2024-06-30)

- Gross loss amounted to kDKK -9,001 (kDKK -9,029) Operating loss amounted to kDKK -10,969 (kDKK -10,658) Loss before tax amounted to kDKK -12,112 (kDKK -10,658) Loss for the period amounted to kDKK -10,737 (kDKK -8,312)
- Total assets amounted to kDKK 28,847 (kDKK 46,331)
- Equity ratio amounted to 43.9% (95.8%)
- Earnings per share amounted to DKK -0.54 (DKK -0.41)

H1 (2024-01-01 - 2024-06-30)

- Gross loss amounted to kDKK -16,385 (kDKK -13,685)

- Operating loss amounted to kDKK -20,345 (kDKK -16,842) Loss before tax amounted to kDKK -21,479 (kDKK -16,844) Loss for the period amounted to kDKK -18,729 (kDKK -13,138) Total assets amounted to kDKK 28,847 (kDKK 46,331)

Equity ratio amounted to 43.9% (95.8%) Earnings per share amounted to DKK -0.94 (DKK -0.66)

Numbers in parenthesis are the numbers from the same period in 2023.

Definitions

Equity ratio: Shareholders equity as a proportion of total assets. Earnings per share: Profit/Loss for the period divided by average number of shares.

Secured funding for our development plans and strong momentum in our partnership with Curium

During the second quarter of 2024, we have continued to build on our successes from the past year. We have enrolled the first patient in our phase 2 trial with uTRACE in prostate cancer and showed the rapid progress in our partnership with Curium, receiving the second milestone payment under this collaboration. We also announced a capital raise aimed at further strengthening the company's finances. The fund raised includes a directed share issue, a loan facility, and warrants which has initially provided DKK 27.8 million as first step, and the package is aimed to provide up to DKK 120 million, extending our cash runway well in to the second half of 2025.

Providing a strong financial base with potential new funding of up to DKK 120 million

Since we announced the cancellation of the rights issue in March, we have been working tirelessly to structure a capitalization and funding plan which will both create value for our shareholders and enable us to continue momentum in our development activities. The package of the directed issue, loan financing and planned warrant exercises gives us an important capital injection so that we can continue to advance our theranostic platform approach and develop in parallel both uTRACE® for improved diagnostics and uTREAT® for better therapeutic options for certain cancer types. The transaction ensures potential total new funding up to DKK 120 million and strategic flexibility, with the full financing extending the cash runway well in to the second half of 2025.

The sharpened focus on our therapeutic platform reflects current thinking in both the scientific community and the pharmaceutical industry to provide a combined approach for both diagnosis and treatment. During Q1 we announced our aim to investigate clinically uTREAT[®] across five different cancer types to achieve clinical proof of concept for our therapy option.

On the diagnostic side of our theranostics solution, since signing the partnership with Curium last year for the development of uTRACE[®] in prostate cancer, we have moved rapidly. We were therefore delighted to be able to show this progress with the announcement of the first milestone related to validation of GMP manufacturing of the finished product.

Progressing our phase 2 trial with uTRACE[®] in Prostate Cancer

The enrollment of the first patient in our phase 2 trial under the deal with Curium marks an important step in the development of the diagnosis arm of our theranostic platform. We are grateful to the patients and doctors involved in this trial in supporting our efforts to develop uTRACE[®] as a potential alternative option to the use of biopsies for people with prostate cancer and the last patient in the trial is expected to be included in Q2 2025. Under the agreement signed with Curium in 2023, Curasight is eligible to receive up to USD 70 million in development and commercial milestones plus doubledigit royalties on sales upon commercialization.

Demonstrating "proof-of-concept" for uTREAT®

Through discussions with big pharma and key opinion leaders we understand the need to be able to demonstrate clinical "proof-of-concept" for uTREAT[®] as soon as possible. Therefore, we are in the process of identifying a rapid route to pursue a single indication where we can run a relatively cost effective small trial that can be completed in a relatively short time frame to provide this first validation of uTREAT[®]. As the uPAR-biomarker is cancer specific but not cancer type specific it works across cancer types. Therefore, our aim is to find a route for rapid proof of concept which we can then follow up with a larger and more complex basket study with five different indications to provide further broader evidence of the application in different cancer types.

Anticipating progress rest of 2024

Looking ahead to the rest of 2024, we anticipate further progress in our pipeline. Radionuclide Ligand Therapy (RLT) continues to be in focus as an important option within radiotherapy in cancer, so we are also focused on continuing ongoing discussions with different players within this area in the pharmaceutical industry. At the same time, we expect to further secure our financial base with the execution of the next step in our financing package, which includes the issuance of TO2 and TO3 warrants to all of our current shareholders, where TO2 can be exercised in the 4th quarter of 2024.

As I look towards an exciting second half of the year I would like to extend my gratitude for your continued trust in Curasight.

Sincerely,

Ulrich Krasilnikoff CEO, Curasight A/S

Highlights Q2 and after

On April 12, Curasight announced that the Chair of the Board of Directors, Per Falholt, has announced that he wishes to step down from the Board of Directors with immediate effect. Kirsten Drejer has been elected as the new Chair of the Board of Directors.

On April 16, Curasight announced the approval of a clinical trial application (CTA) from the European Medicines Agency (EMA) for the investigation of uTRACE[®] in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.



On June 12, Curasight announced the enrolment of the first patient in the Phase 2 trial using uTRACE® PET imaging technology for the improved diagnosis in prostate cancer. The news triggers the second USD 500.000 milestone under the agreement with Curium Inc., signed in May 2023. uTRACE® is part of Curasights Theranostic platform using the uPAR target for improved diagnosis and treatment (uTREAT®) of certain cancers.

On June 14, Curasight' BoD resolved to execute directed issues of shares of a total of approximately DKK 7.8 million. The Company also intends to execute a directed issue of units, consisting of warrants, to Fenja Capital II A/S as well as a preferential rights issue of units, consisting of warrants, to the existing shareholders. Curasight has also secured a loan facility of in total DKK 20 million from Fenja and from the loan facility the Company has decided to immediately draw a tranche of DKK 10 million. The proceeds from the total capitalization are to be used to fund the advancement of Curasight's pipeline within the field of radiopharmaceuticals, enabling the parallel development of the company's diagnostic uTRACE® platform and radioligand therapy uTREAT® platform, as well as support activities connected to the ongoing collaboration with Curium Inc. The transaction ensures potential new funding up to DKK 120 million and strategic flexibility, with the full financing extending the cash runway into the second half of 2025.

On July 2, Curasight held an Extraordinary General Meeting to resolve the authorization of the BoD to issue warrants. The Minutes with summarised decisions are available on Curasight's website.

On July 30, Curasight announced that it had re-issued a total of 59,132 warrants as part of the Company's existing long-term incentive program covering the Company's Board of Directors, Executive Management and other key employees.

Half-year report Q2 2024

Key figures

CEO letter

Highlights

About Curasight

Financial statements

By combining diagnostics with therapy – Curasight is on a mission to improve the lives of millions of people with cancer

Curasight A/S in short

Curasight is a clinical phase II company based in Copenhagen, Denmark. Curasight is the pioneer behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT[®] radiation therapy with the precise uTRACE[®] diagnostics. Several investigatorinitiated phase II clinical trials have been completed or are currently undertaken.

PET-imaging, usually combined with CT as PET/ CT is used to create images in which the biology of the disease can be studied. The principle is that a radiolabelled tracer is injected and bound to the tumor targets in the tissues, e.g. uPAR, after which the radioactivity can be located with the help of a PETscanner. Together with his team, Professor Andreas Kjaer, developed a platform based on the radiolabelled PET-tracer uTRACE[®], Curasight's novel product that highlights the cancer biomarker uPAR. By injecting the patient with uTRACE[®], one can both image where the cancer is located and determine its level of aggressiveness.

uTRACE^{*} **images cancer** aggressiveness and invasive potential. By imaging this, Curasight's technology can diagnose and determine which therapeutic strategy should be pursued, e.g. if the patient needs treatment (e.g. surgery such as prostatectomy and/or radiotherapy) or not. In addition, uTRACE^{*} will be used for theranostics (principle of combined therapy and diagnostics) and precision medicine, selecting the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

uTRACE® solution is expected to have major

advantages in the future evaluation of prostate cancer because it is expected to help determine what type of treatment – and in particular if surgery – is necessary. Today most prostate cancer patients having prostatectomies performed are operated unnecessarily and most of these patients (up to 70 percent) experience some degree of side effects, such as impotence. The company believes that using Curasight's product and diagnosis could improve patient management. uTRACE[®] is designed to provide a more accurate categorisation of a patient's tumor, supporting more tailored treatment plans allowing which can identify the necessary treatment at the right time.

Curasight's technology has been tested phase II academic clinical trials. According to the board's assessments, there is currently no other early-stage biotech company in the field of PET tracer development that has their technology tested in a broader portfolio of ongoing and planned clinical trials in humans (whether investigator-initiated and academically sponsored or industry-sponsored trials), in many different cancer indications. In 2017 a phase I/IIa first-in-human academic clinical trial with uTRACE[®] was completed. In 2018 a phase IIb academic clinical trial with uTRACE[®] in breast cancer; in 2020 a phase II academic study in prostate cancer in 2021/2022 two academic studies in head-and-neck cancer and neuroendocrine tumors, respectively, were completed, and in 2023 the study in brain cancer was completed. A study in lung cancer is ongoing.



uPAR PET imaging with uTRACE^{*} for improved evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trails.

(Therapy) uTREAT[®]

uPAR targeted radionuclide therapy is using uTRACE[®] together with radiation therapy to locally irradiate cancer with limited irradiation of healthy tissue.

uPAR Theranostic

The combination of non-invasive PET imaging (Diagnostic) and targeted radionuclide therapy (Therapy) is together known at Theranostics.

Targeted radionuclide therapy (theranostics) is

expected to be the radiation therapy of the future. With the promising results obtained within diagnostics, Curasight now also pursues uPAR targeted radionuclide therapy using the uTRACE® ligand but "armed" with short-range (1 mm) radiation therapy. In brief, the therapeutic ligand will be injected into a vein after which it will circulate and bind to all cancer cells in the body expressing uPAR and locally irradiate cancer with limited irradiation of healthy tissue. This concept represents a gentler form of radiotherapy compared to traditional external radiation therapy and is therefore by many considered the "radiation therapy of tomorrow". As PET imaging and radionuclide therapy are based on the same uPAR binding peptide, a uTRACE[®]-scan can precisely predict where subsequent targeted radiation therapy will be delivered (theranostic principle).

Business model and critical path to regulatory approval

Curasight aims to etablish its theranostic approach using imaging targeting the uPAR protein to improve the diagnosis and treatment of selective cancers. The company's uTRACE[®] platform can be used as an alternative to biopsies to discover and characterise tumors and the uTREAT[®] platform can then be used for more targeted treatment of the tumor.

Currently Curasight is focused on generating data with both uTRACE® and uTREAT® in cancers including prostate cancer, glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer. Each of these cancers offer different development opportunities and it is Curasight's aim, based on clinical data, to find experienced partners who can collaborate on the later stages of development of uTRACE® and uTREAT®. Currently Curasight has a partnership for uTRACE® in prostate cancer with Curium, a leader in the field of radionuclide medicine.

Additionally, as a small and nimble company, Curasight seeks out highly specialised partners to support its operational drug development, for example with research and clinical contract organisations who are highly competent in the field of both diagnostic and therapeutic radiopharmaceuticals. By forming partnerships with Contract Development Manufacturing Organisations (CDMOs), and Clinical Research Organisations (CROs) we ensure access to top development manufacturing expertise and capacity and skills in conducting manufacturing of investigational medicine and clinical trials in accordance with good manufacturing (GMP) and clinical practice (GCP). We have now signed an agreement with Minerva Imaging ApS considered to be the optimal CDMO for the manufacture of the Investigational Medicinal Product for our coming clinical study with uTRACE[®]. Likewise, we have finalised the contract with the CRO partner for our upcoming Phase 2 trial in prostate cancer with a 64Cu-labeled version of uTRACE[®].

Outlook for Curasight

Curasight is expanding and accelerating its clinical therapeutic strategy with the addition of a new Phase I/IIa trial in a single indication to demonstrate clinical "proof-of-concept" for uTREAT[®]. A route has been identified with the aim to pursue a single indication for a relatively small trial that can be completed rapidly to provide this first validation of uTREAT[®]. As the uPAR-biomarker is cancer specific but not cancer type specific it works across cancer types, we can document the efficacy and safety in a cost effective and rapid way in a first indication and then run the larger and more complex basket study with five different indications to provide further broader evidence of the application in different cancer types. The plan is to enroll the first patient in H1 2025.

After completion a new Phase I/IIa in a single indication, Curasight plans to expande and accelerate its clinical therapeutic strategy with the addition of a new Phase I/IIa basket trial to include a total of five cancer indications in the same trial. The trial will investigate Curasight's theranostic approach by testing the diagnosis platform uTRACE[®] and treatment platform uTREAT[®] in:

- Brain cancer (Glioblastoma)
- Neuroendocrine tumors (NET)
- Head and Neck cancer
- Non-Small Cell Lung cancers (NSCLC), and
- Pancreatic cancer.

The new Phase I/IIa basket trial will apply Curasight's uPAR theranostic platform approach combining diagnosis (uTRACE[®]) and therapy (uTREAT[®]) and expect to initiate this trial in 2026.

Curasight is committed to accelerating the development of its uTREAT[®] therapeutic platform in order to develop both uTREAT[®] and its diagnosis platform uTRACE[®] in parallel, to deliver better options to patients with certain types of cancer.

Furthermore, Curasight is looking into how to unfold further our platform and how to broaden the mission to realize the vast potential of uTRACE[®] for diagnosing and uTREAT[®] for targeted radionuclide therapy in other cancer types where uPAR is also expressed.



Key figures

About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Curasight's research and development efforts aim to address this challenge and improve the lives of patients facing aggressive brain cancer. Curasight's first goal is to advance its lead platforms uTREAT® (used for therapy) and uTRACE® (used for diagnosing) to improve outcomes for the approx. 65,000 patients in the US and EU diagnosed annually with brain tumours. Accordingly, approximately 30,000 patients are diagnosed each year with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for Orphan Drug Designation; moreover, because of the high unmet need, platforms targeting it are more likely to gualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.

About neuroendocrine tumors

Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body. The main findings from the phase II trial with uTRACE[®] were that uPAR-positive lesions were seen in most NET patients and that uPAR PET was prognostic, and that uPAR will be a promising target for therapy in NET patients.

About head and neck cancer

Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years. The main finding from the Phase II trial using uTRACE® was that patients with high uptake on uPAR-PET compared to those with a low uptake had an 8.5-fold poorer prognosis regarding relapse-free survival. The conclusion from the trial was that uPAR-PET could become valuable regarding planning of therapy and follow-up in head and neck cancer patients. In addition, the presence of uPAR in head and neck cancer patients and in particular, in those with the most aggressive disease, also formed the basis for pursuing uPARtargeted radionuclide therapy (uTREAT®) in this cancer type.

About Non Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. NSCLC is the most common type of lung cancer with approximately 700,000 patients being diagnosed each year in the US and EU alone. The 5-year survival rate in the US is around 28 %. Despite advances, there is a need for more effective therapies. Curasight's preclinical studies show uTREAT[®] effective in treating non-small cell lung cancer (NSCLC). Preliminary data from the investigatorinitiated study presented at WMIC in Praque last year, demonstrates that almost all NSCLC tumors are uPAR positive and thus would be eligible for uTREAT[®].

About Pancreatic Cancer

Pancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer in 2024.

Strategic partnerships

Due to the very encouraging results from the finalised investigator-initiated clinical phase-II study in Prostate Cancer, Curasight has entered into a collaborative partnership with Curium to accelerate the product development of uTRACE[®] as a more flexible and non-invasive risk stratification tool compared to the present gold standard (biopsy), for prostate cancer patients entering or being followed in active surveillance programs. The first milestone payment Curium has been received by us.

To support and accelerate the strategic business development, discussions are currently ongoing with a number of major pharma companies with a view to uncover opportunities and interest in uTRACE[®] and uTREAT[®].

Key clinical milestones 2024

(i)	H2 2024: uTRACE [®] – Last patient included – part I in uTRACE [®] ph 2 trial (Curium partnership)
(ii)	H2 2024: uTRACE [®] – Preliminary efficacy data – part I in uTRACE [®] ph 2 trail (Curium partnership)

utreat	The	erap	eutic	: Pr	og	ra	m		
THERAPEUTIC SOLUTIONS	Pre-cli	nical	Phase I	Р	hase II		Phase III		
oonsor: Curasight agnostic platform: uTRA	CE [®] and uTREAT	-0							
GBM Glioblastoma (Brain cancer)									
NSCLC Non-Small Cell Lung cancers	s	Completed		Phase I/IIa tria	lin				
NEN Neuroendocrine neoplasms	Com		planning Basket trial* ac selected cance Applying the theranostic ap	cross er diseases			llb/III to anned		
HNSCC Head & Neck Cancer			(uTrace) and th (uTrace) and th	gnostic					
PaC Pancreatic cancer									

Highlights

About Curasight

Financial statements

utra DIAGNOSTIC SOLUTIONS

Key figures

CEOlottor

Sponsor: Curasight Partner: Curium Inc. Diagnostic platform: uTRACE®

Partnered Project



*) Investigated for diagnostic performance for non-invasive classification of ISUP grades among patients with localised, untreated prostate cancer. ** Investigator-initiated study

Key figures	CEO letter	Highlights	About Curasight	Financial statements
Utrace DIAGNOSTIC SOLUTIONS	Inv Pre-cl			ed Trials Phase III
Sponsor: National Universi Diagnostic platform: uTR	sity Hospital of De ACE®	nmark (Rigshospitalet)	, l	
GBM Glioblastoma (Brain cance	r)		Completed	
PCa Prostate cancer			Completed	
NEN Neuroendocrine neoplasm	s		Completed	Results from uTRACE [®] IITs are used as supportive data
HNSCC Head & Neck Cancer			Completed	in ongoing partner project with Curium as well as in potential future partnering projects and in the planning
NSCLC Non-Small Cell Lung cance	er		Ongoing	of our therapeutic program with a theranostic approach.
BC Breast cancer			Completed	
UBC Urinary bladder cancer			Completed**	

*) Investigator Initiated Trails = IITs, >400 patients have received utrace in these Investigator Initiated Trials

**) Completed with fewer patients than planned for technical reasons

Financial analyst coverage



since: June, 2021

Type: Commissioned

Frequency: Continuously

Areas: Curasight's operations, platforms, markets and competitors





since: October, 2023

Type: Commissioned

Frequency: Continuously

Areas: Curasight's operations, platforms, markets and competitors



KAPITAL ---PARTNER

since: August, 2021

Type: Commissioned

Frequency: Continuously

Areas: Curasight's operations, platforms, markets and competitors



Half-year report Q2 2024

Corporate Information

Shareholders

The table below presents the management's shareholdings in Curasight.

Name	Votes & capital (%)
AK 2014 Holding ApS ¹	30,24
UK Curacap ApS ²	20,01
CHN Holding ApS ³	12,11
Madsen Holding 2013 ApS ⁴	4,57
LT 2003 ApS⁵	2,95
Charlotte Vedel ⁶	0,20
Hanne Damgaard Jensen ⁷	0,20
Kirsten Drejer ⁸	0,02

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer

2. Owned by CEO and Board Member Ulrich Krasilnikoff

Owned by co-founder Carsten H Nielsen

4. Owned by Co-founder and Director CMC, Jacob Madsen

5. Owned by Deputy Chairman of the Board, Lars Trolle

6. Member of the Board of Directors

7. CDO & COO

8. Chair of the Board of Directors

The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020. The short name/ ticker is CURAS, and the ISIN code is DK0061295797. As of June 30, 2024, the number of shares was 19,893,891 (19,893,891). All shares have equal rights to the Company's assets and results.

Long-term incentive program

Curasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Company's Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Lars Trolle (dept. chairman of the Board of Directors), Charlotte Vedel (member of the Board of Directors) and Kirsten Aarup Drejer (Chair of the Board of Directors).

For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasilnikoff (CEO), Andreas Kjær (CSO), Hanne Damgaard Jensen (CDO), Nic Gillings (Head of Quality Assurance and Regulatory Affairs) and Jacob Madsen (Director CMC).

On July 30, 2024, Curasight re-issued a total of 59,132 (previously lapsed) warrants with rights to subscribe for a total of DKK 2,956.60 nominally worth of shares in the Company. 42,460 warrants will be re-issued and allocated to Carsten Deleuran (Finance Director) as part of the ordinary incentive program covering the Executive Management and key employees of the Company. 16,672 warrants will be re-issued and allocated to Chair of the Board of Directors Kirsten Drejer as part of the ordinary incentive program covering the Board of Directors of the Company.

Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the prospectus published by the Company in 2020. The prospectus is available on Curasight's website: www.curasight.com/investor/ipo-2020/

Accounting policy

The interim report is presented in accordance with the provisions of the Danish Financial Statements Act (Årsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class.

Auditor's review

The Half-year report has not been reviewed by the Company's auditor.

Financial calendar	
Interim report Q3 2024	November 21, 2024
Year-end report Q4 2024	February 20, 2025

Financial statements

Income statement

Operating loss before tax for the second quarter of 2024 amounted to kDKK -12,112 (kDKK -10,658). Operating loss before tax for the first six months of 2024 amounted to kDKK -21,479 (kDKK -16,844).

Loss before depreciation, amortisation and impairments for the second quarter amounted to kDKK -10,765 (kDKK -10,479) of which staff expenses was kDKK -1,765 (kDKK -1,450). Loss before depreciation, amortisation and impairments for the first six months of 2024 amounted to kDKK -19,938 (kDKK -16,484) of which staff expenses was kDKK -3,552 (kDKK -2,799).

Loss before depreciation, amortisation and impairments comprise of revenue, clinical expenses, patent expenses, staff expenses and other business expenses.


Balance sheet

Per June 30, 2024, the Company's balance sheet amounted to kDKK 28,847 (46,331). The assets consisted primarily of acquired IP-rights totaling kDKK 7,234 related to the development of uTRACE[®] and uTREAT[®] and cash amounted to kDKK 8,384. The equity and liabilities consisted primarily of an equity totaling kDKK 12,654 and short-term debt of kDKK 16,193.

Cash flow

Curasight's total cash flow in Q2 2024 amounted to kDKK -3,493. This post was primarily affected by the Company's loss for the period resulting in cash flow from operating activities of kDKK -13,493 offset by proceeds from loans of kDKK +10,000.

Cash as of June 30, 2024, was kDKK 8,384 (kDKK 32,104).





Income statement

(kDKK)	Q2 2024*	Q2 2023*	H1 2024*	H1 2023*	Q1-Q4 2023
Gross loss	-9,001	-9,029	-16,385	-13,685	-25,729
Staff expenses	-1,765	-1,450	-3,552	-2,799	-6,395
Loss before depreciation, amortisation, write-downs and impairment losses	-10,765	-10,479	-19,938	-16,484	-32,124
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-204	-179	-407	-358	-1,090
Operating loss	-10,969	-10,658	-20,345	-16,845	-33,214
Net financial expenses	-1,143	0	-1,134	-2	-6
Loss before tax	-12,112	-10,658	-21,479	-16,844	-33,220
Tax on loss for the period	1,375	2,346	2,750	3,706	7,051
Loss for the period	-10,737	-8,312	-18,729	-13,138	-26,169

*) Unaudited figures

Balance sheet—Assets

(KDKK)	2024-06-30*	2023-06-30*	2023-12-31
Acquired patents	7,234	6,703	7,641
Intangible assets	7,234	6,703	7,641
Other fixtures and fittings, tools and equipment	0	119	0
Property, plant and equipment	0	119	0
Deposits	51	44	51
Total investments	51	44	51
Total non-current assets	7,285	6,866	7,693
Other receivables	4,928	7,259	5,469
Income tax receivables	8,250	102	5,500
Total receivables	13,178	7,361	10,969
Cash at bank and in hand	8,384	32,104	20,080
Total current assets	21,562	39,456	31,049
Assets	28,847	46,331	38,742

*) Unaudited figures

Balance sheet—Liabilities and equity

(kDKK)	2024-06-30*	2023-06-30*	2023-12-31
Share capital	995	995	995
Retained earnings	11,659	43,419	30,388
Equity	12,654	44,414	31,383
Trade payables	5,892	612	6,922
Deferred income	0	1,128	0
Other payables	201	177	437
Debt	10,100	0	0
Short term-debt	16,193	1,917	7,359
Debt	16,193	1,917	7,359
Liabilities and equity	28,847	46,331	38,742

Equity-Q2* 2024

(kDKK)		Share Premium	Retained	
Change in equity Q2 2024	Share capital	Account	earnings	Total
Equity at April 1, 2024	995	0	22,396	23,391
Net profit/loss for the period	0	0	-10,737	-10,737
Equity at June 30, 2024	995	0	11,659	12,654

Equity-Q2* 2023

(kDKK) Change in equity Q2 2023	Share capital	Share Premium Account	Retained earnings	Total
Equity at April 1, 2023	995	Ο	51,731	52,726
Net profit/loss for the period	0	0	-8,312	-8,312
Equity at June 30, 2023	995	0	43,419	44,414

*) Unaudited figures

Equity—H1* 2024

(kDKK)		Share	Detained	
Change in equity H1 2024	Share capital	Premium Account	Retained earnings	Total
Equity at January 1, 2024	995	0	30,388	31,383
Net profit/loss for the period	0	0	-18,729	-18,729
Equity at June 30, 2024	995	0	11,659	12,654

Equity—H1* 2023

(kDKK) Change in equity H1 2023	Share capital	Share Premium Account	Retained earnings	Total
Equity at January 1, 2023	995	ο	56,557	57,552
Net profit/loss for the period	0	0	-13,138	-13,138
Equity at June 30 2023	995	0	43,419	44,414

Equity—FY 2023

(kDKK)		Share Premium	Retained	
Change in equity Q1-Q4 2023	Share capital	Account	earnings	Total
Equity at 1 January, 2023	995	0	56,557	57,552
Net profit/loss for the period	0	0	-26,169	-26,169
Equity at 31 December 2023	995	0	30,388	31,383

*) Unaudited figures

Cash flow statement

(kDKK)	Q2 2024*	Q2 2023*	H1 2024*	H1 2023*	Q1-Q4 2023
Loss for the period	-10,737	-8,312	-18,729	-13,138	-26,169
Adjustments	-29	179	-1,209	358	-5,894
Change in working capital	-1,658	-3,738	-725	-5,059	1,073
Cash flow from operating activities before net financials	-12,450	-11,871	-20,663	-17,839	-30,990
Interest expenses and similar expenses paid	-1,043	0	-1,034	-2	-6
Income tax received/paid	0	0	0	0	1,139
Cash flow from operating activities	-13,493	-11,871	-21,697	-17,841	-29,857
Change in deposits	0	0	0	0	-8
Cash flows from investing activities	0	0	0	0	-8
Proceeds from loans	10,000	0	10,000	0	0
Cash flows from financing activities	10,000	0	10,000	0	0
Total cash flows for the period	-3,493	-11,871	-11,697	-17,841	-29,865
Cash, beginning of the period	11,877	43,975	20,080	49,945	49,945
Cash, end of the period	8,384	32,104	8,383	32,104	20,080
Cash, end of the period	8,384	32,104	8,384	32,104	20,080
Total	8,384	32,104	8,384	32,104	20,080

*) Unaudited figures

Statement by the Board of Directors

The Board of Directors provide their assurance that the interim report provides a fair and true overview of the Company's operations, financial position, and results.

København N, August 22, 2024 Curasight A/S

Board of Directors

Kirsten Drejer Chair of the Board Lars Trolle Dept. chair of the Board

Charlotte Vedel Board member Andreas Kjær Board member

Ulrich Krasilnikoff Board member and CEO

> Contact information Curasight A/S Ole Maaløes Vej 3 2200 Copenhagen, Denmark Email: info@curasight.com Phone: +4522830160

curasight

Curasight's team are pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT[®] radiation therapy, with the precise uTRACE[®] diagnostics.